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ABSTRACT Characterization of rhodamine 123 as functional assay for MDR has been primarily focused on P-glycoprotein-
mediated MDR. Several studies have suggested that Rh123 is also a substrate for MRP1. However, no quantitative studies of
the MRP1-mediated efﬂux of rhodamines have, up to now, been performed. Measurement of the kinetic characteristics of
substrate transport is a powerful approach to enhancing our understanding of their function and mechanism. In the present
study, we have used a continuous ﬂuorescence assay with four rhodamine dyes (rhodamine 6G, tetramethylrosamine,
tetramethylrhodamine ethyl ester, and tetramethylrhodamine methyl ester) to quantify drug transport by MRP1 in living GLC4/
ADR cells. The formation of a substrate concentration gradient was observed. MRP1-mediated transport of rhodamine was
glutathione-dependent. The kinetics parameter, ka ¼ VM/km, was very similar for the four rhodamine analogs but ;10-fold less
than the values of the same parameter determined previously for the MRP1-mediated efﬂux of anthracycline. The ﬁndings
presented here are the ﬁrst to show quantitative information about the kinetics parameters for MRP1-mediated efﬂux of
rhodamine dyes.
INTRODUCTION
A major obstacle impeding the success of chemotherapy is
multidrug resistance (MDR). The classical MDR phenotype
is characterized by cross-resistance to a wide variety of
structurally unrelated chemotherapeutic agents of natu-
ral origin after being exposed to only one. The role of
P-glycoprotein (P-gp) and the multidrug resistance protein
(MRP1) in MDR, in vitro, are uncontested (Cole and Dee-
ley, 1998; Nielsen and Skovsgaard, 1992). Both proteins
are members of the ATP-Binding-Cassette superfamily of
transport proteins that lower the intracellular drug content
through active drug efﬂux. Transfection experiments with
the mdr-1 gene (Fojo et al., 1987) or the mrp-gene (Grant
et al., 1994) have demonstrated that overexpression of these
genes was sufﬁcient to render otherwise drug-sensitive cells
multidrug resistant.
Characterization of drug retention as functional assays for
MDR has been primarily focused on P-gp-mediated MDR,
and the recognition that Rh 123 is substrate for P-gp that can
be applied at noncytotoxic concentrations has stimulated
the use of this agent in ﬂow cytometric drug retention stud-
ies. After the discovery of MRP1 in 1996, studies were
undertaken to determine if agents used to evaluate P-gp
function also can be used to evaluate MRP function. Thus,
cellular retention of rhodamine 123 was studied in MRP1-
expressing cell lines. Several studies have suggested that
Rh123 is a substrate for MRP1 (Zaman et al., 1994;
Twentyman et al., 1994; Minderman et al., 1996); however,
no quantitative studies of the MRP1-mediated efﬂux of
rhodamine have, up to now, been performed.
In this article, using two types of measurements, rate and
steady-state, with the latter being performed under single-
cell conditions, we have derived values for the internal con-
centration of free rhodamine, and hence values for the real
rate of outward pumping of rhodamine. In addition, the use
of potassium and a potassium carrier to eliminate the ef-
fect of membrane potential makes a very useful simpliﬁca-
tion. This was done using intact GLC4/ADR cells. We are
therefore able to present data that quantitatively character-
ized the transport by MRP1 of four rhodamine analogs:
rhodamine 6G (Rh 6G), tetramethylrosamine (TMR), tet-
ramethylrhodamine ethyl ester or rhodamine I (Rh I), and
tetramethylrhodamine methyl ester or rhodamine II (Rh II).
The results are compared with those obtained in the same cell
line with other substrates versus those obtained in cells hav-
ing a P-gp-mediated MDR phenotype.
MATERIALS AND METHODS
Drugs and chemicals
Rhodamine 6G (Rh 6G) was purchased from Sigma (St. Louis, MO).
Tetramethylrosamine (TMR), tetramethylrhodamine ethyl ester or rhoda-
mine I (Rh I), and tetramethylrhodamine methyl ester or rhodamine II (Rh II)
were purchased from Molecular Probes (Eugene, OR). Stock solution of
rhodamine, 10-3M, were prepared in ethanol. Puriﬁed daunorubicin (DNR)
was kindly provided by Pharmacia-Upjohn Laboratories (Milano, Italy).
Triton X-100, valinomycin, FCCP, L-buthionine-(s,r) sulphoximine (BSO),
and concanamycin A were from Sigma. Valinomycin and FCCP were
dissolved in ethanol. All the reagents were of the highest quality available
and deionized double-distilled water was used throughout the experiments.
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Some experiments were performed in HEPES/Na1 buffer solutions
containing 20 mM HEPES plus 132 mM NaCl, 3.5 mM KCl, 1 mM CaCl2,
and 0.5 mM MgCl2, 5 mM glucose at pH 7.3. However, most of the
experiments were performed in HEPES/K1 buffer solution: to dissipate
membrane potential, high K1, low Cl buffer was made by equimolar
substitution of K-methanesulfonate for NaCl, 10 nM valinomycin, and 1 mM
FCCP was added. We have checked that at these concentrations neither
valinomycin nor FCCP inhibits the MRP1-mediated efﬂux of drug. K-
methanesulfonate was made by titration of methanesulfonic acid with KOH
before addition to buffer (Piwnica-Worms et al., 1983).
Cell lines and cultures
GLC4 and the MRP1-expressing GLC4/ADR cells (Zijlstra et al., 1987)
were cultured in RPMI 1640 medium supplemented with 10% fetal calf
serum in a humidiﬁed incubator with 5% CO2. The resistant GLC4/ADR
cells were cultured with 1.2 mM doxorubicin until 1–4 weeks before
experiments. Cell cultures used for experiments were split 1:2 one day
before use to ensure logarithmic growth. Cell viability was assessed by
Trypan blue exclusion and was >95% under the various experimental
conditions used. Cell counting and cell diameter were determined using
a Coulter Channelyzer 256 (Beckman, St. Louis, MO). The curve
distribution of the cell number vs. cell radius had a Gaussian shape with
a maximum corresponding to mean cell radius of 12.5 mm and 75% of the
cells had a radius equal to 12.5 6 1.5 mm, which yields a mean volume 1.0
6 0.3 3 1012 L. The cytotoxicity of one rhodamine derivative, RhII, was
determined by incubating cells (105) with different concentrations of the
compound for 72 h in standard 6-well plates. Three independent experiments
were performed. Then the IC50 values (50% inhibitory drug concentrations)
were determined by counting the cells using a Coulter counter. The
resistance factor (RF) was deﬁned as the IC50 for the resistant cells divided
by the IC50 for the corresponding sensitive cells.
GSH depletion
To examine the effect of glutathione depletion by L-buthionine sulphox-
imine on rhodamine efﬂux, cells were cultured in the presence of 25 mM
BSO for 24 h. Intracellular GSH was quantiﬁed using an enzymatic
technique (Salerno and Garnier-Suillerot, 2001).
Real-time ﬂuorescence measurement of drug
transport in living cells
Intracellular rhodamine accumulation was measured with a ﬂow cytometer
(Becton-Dickinson, Beckman, St. Louis, MO). Cells, 106/ml, were put in the
K1 buffer at 378C and a small volume of the mother rhodamine solution was
quickly added to get a CT rhodamine concentration. Fluorescence intensity
was measured continuously until steady state was reached.
Mathematical calculations
The mathematical symbols used are the following:
N 3 109 is the number of cells per liter.
Vcell is the volume of one cell (;10
12 L cell1).
Ce is the extracellular drug concentration.
C is the concentration of internal rhodamine bound to its receptors.
Ci is the concentration of free internal rhodamine.
CT, the total concentration of rhodamine added to the cells, is equal to
the concentration of rhodamine in the extracellular medium plus the
concentration of rhodamine, bound and free, inside the cells:
CT ¼ Ce1N3 1093 ðC1 CiÞ3Vcell: (1)
K is the mean binding constant for rhodamine to its receptors.
[receptors] is the concentration of internal receptors for rhodamine.
K ¼ C/Ci 3 [receptors] or K ¼ b 3 [receptors] with b ¼ C/Ci.
F is the molar ﬂuorescence of rhodamine free in the cytosol.
r is the mean ﬂuorescence quantum yield for rhodamine bound to its
receptors.
A ¼ F 3 (1 1 b 3 r) is the proportionality constant between the
ﬂuorescence intensity recorded via ﬂow cytometry and Ci.
V1, the rate of passive uptake for rhodamine, is equal to the number of
moles that enter by passive diffusion into one cell per second.
V, the rate of passive efﬂux for rhodamine, is equal to the number of
moles that leave one cell by passive diffusion per second.
k is the passive permeability rate constant (which takes into account the
permeability constant of the molecule, the membrane exchange area
per cell).
V1 ¼ k 3 Ce and V ¼ k 3 Ci.
Va, the rate for outward pumping, is equal to the number of moles that
are pumped out by MRP1, per cell and per second.
ka is the rate constant for outward pumping at limiting low substrate
concentration.
Va ¼ ka 3 Ci.
We intend to derive, from the data ka, the rate constant for outward
pumping at limiting low substrate concentration, and for this purpose we
need to determine 1), the concentration of free internal rhodamine; 2), the
mean binding constant for rhodamine to its receptors, whatever they are; 3),
the mean ﬂuorescence quantum yield for rhodamine bound to its receptors,
whatever they are; 4), the passive permeability rate constant; and 5), the rate
constant for outward pumping at limiting low substrate concentration.
The determination of the kinetic parameters, e.g., the maximum rate, VM,
and the Michaelis constant, Km, characteristic of the transporter-mediated
efﬂux of drugs, required the measurement of Va and Ci. When Va can be
determined for various intracellular free drug concentrations Ci, the maximal
efﬂux rate (VM) and the apparent Michaelis-Menten constant (Km) can be
computed by nonlinear regression analysis of transport velocity Va vs. Ci,
assuming that the transport follows the Michaelis equation
Va ¼ VM3 Ci=ðKm1 CiÞ: (2)
In many cases, the complete curve Va ¼ f(Ci) cannot be obtained and
therefore it is not possible to obtain these two parameters characteristic of
a transporter. However, if Ci is much lower than Km, Eq. 2 becomes
Va; ðVM=ðKmÞ3 Ci
or
Va ¼ ka3 Ci: (3)
In this work, the rate of MRP1-associated efﬂux of rhodamine was
calculated at the steady state, taking into account the following points: 1), the
diffusion (inﬂux and efﬂux) of rhodamine through the membrane is passive,
so it obeys Fick’s law; 2), whatever the type of cells, i.e., either drug-
sensitive or drug-resistant, at steady state the rate of rhodamine inﬂux (V1)s
is equal to that of rhodamine efﬂux; and 3), for drug-resistant cells, the efﬂux
is composed of two terms: a passive efﬂux of the molecule (V)s, and an
MRP-mediated efﬂux of the molecule (Va)s. It follows that
ðV1 Þs ¼ ðVÞs1 ðVaÞs
or
ðVaÞs ¼ ðV1 Þs ðVÞs
ðVaÞs ¼ k3 ðCe  CiÞs: (4)
Taking into account Eqs. 3 and 4, this becomes
ka ¼ k3 ½ðCe=CiÞ  1: (5)
Therefore, ka determination requires k, Ce, and Ci.
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As it will be demonstrated below, the determination of k requires the
knowledge ofF (the molar ﬂuorescence of rhodamine free in the cytosol), of
r (the mean ﬂuorescence quantum yield for rhodamine bound to its receptors
whatever they are), and of b ¼ C/Ci. For this purpose, sensitive cells were
incubated with rhodamine in K1 buffer. Under these experimental
conditions, where Dc ¼ 0, the positively-charged rhodamines cannot
accumulate inside mitochondria. However, they can interact with different
receptors within the cell. The intracellular concentration of rhodamine bound
to these receptors (C) is in thermodynamic equilibrium with the rhodamine
free in the cytosol (Ci). A mean binding constant can be deﬁned as K ¼ C/Ci
3 [receptors]. As we were working under experimental conditions where
the receptors were in large excess compared to the intracellular rhodamine
concentration, the concentration of free receptors could be considered as
constant. It follows that the binding of the different rhodamine to the
receptors can be characterized by b ¼ C/Ci. The concentration of rhodamine
inside the cells is therefore
C1 Ci ¼ Cið11bÞ: (6)
The size of cells used being very homogeneous, we can consider that the
number of moles per cell does not vary so much from one cell to the other.
The ﬂuorescence of one cell measured using ﬂow cytometry (Fcyto) is
therefore proportional to the concentration of rhodamine in the cell. Fcyto is
composed of two terms: the ﬂuorescence of the free internal rhodamine (F3
Ci) and that of the rhodamine bound to its receptors (r 3 F 3 C).
Therefore
Fcyto ¼ F 3 Ci3 ð11 r3bÞ: (7)
Let us consider sensitive cells, N 3 109 L, in K1 buffer, incubated with
rhodamine at concentration CT. At steady state, Ce ¼ Ci, and taking into
account Eqs. 1 and 6, it becomes
Ci ¼ CT=½11 1033N3 ð11bÞ; (8)
and
Fcyto ¼ F 3 ½CT3 ð11b3 rÞ=½11 1033N3 ð11bÞ:
(9)
F, r, and b can then be computed by a nonlinear analysis of Fcyto, measured
at ﬂuorescence steady state, vs. N.
The parameter k was determined from the continuous monitoring of the
ﬂuorescence signal, Fcyto (ﬂow cytometry), when sensitive cells in K
1 buffer
were incubated with rhodamine. Actually, when cells are incubated with
rhodamine, before reaching the steady state, rhodamine enters continuously
into the cells. According to Eq. 6, during dt, the increase of the intracellular
rhodamine concentration is (11 b)3 dCi and the increase of the number of
moles per cell and per second is
Vcell3 ð11bÞ3 ðdCiÞ=dt ¼ k3 ðCe  CiÞ; (10)
or
ðdCiÞ=dt ¼ k3 ðCe  CiÞ=ð11bÞ3Vcell: (11)
The integration of this equation yields
Ci ¼ Ce3 ð1 exp½k3 t=ð11bÞ3VcellÞ: (12)
However, according to Eq. 7, it becomes
Fcyto ¼ð11b3 rÞ3F 3Ce
3 ð1 exp½k3 t=ð11bÞ3VcellÞ;
(13)
which can be written more simply as
Fcyto ¼ að1 exp½b3 tÞ; (13a)
with
a ¼ ð11b3 rÞ3F 3Ce and b ¼ k=ð11bÞ3Vcell:
In this expression, Ce can be taken equal to CT, and the other parameters are
constant. It follows that the term k/(1 1 b) 3 Vcell (and then k), can be
computed by a nonlinear analysis of Fcyto vs. t data. It should be emphasized
that these calculations are valid if the rate of interaction of the dye with its
receptors is much higher than the rate of its passive diffusion through the
membrane.
RESULTS
The rhodamines used in the present study (Fig. 1) have
a permanent positive charge. Due to the membrane
potentials, all these rhodamine dyes were accumulated in
wild-type drug-sensitive cells and were localized mainly
in the mitochondria. Their accumulations were lower in
resistant cells, strongly suggesting that these compounds
were pumped out byMRP1. The aim of the present work was
to determine the efﬁciency of the MRP1-mediated efﬂux of
these rhodamines which can be characterized, as we have
shown in the experimental section, by the coefﬁcient of
active efﬂux ka ¼ k 3 [(Ce /Ci)  1]. This requires the
measurement of 1), the coefﬁcient of passive diffusion k; and
2), the gradient of concentration generated by the pump, e.g.,
the extracellular Ce and the cytosolic Ci free drug concen-
trations at steady state. The following experiments were
designed to determine these three parameters.
If we consider sensitive cells in Na1 buffer, the gradient of
concentration through the plasma membrane depends on
the membrane potential. However, for resistant cells, this
gradient of concentration depends on two parameters: 1), the
plasma membrane potential which tends to make the
cytosolic rhodamine concentration higher than the extracel-
lular one; and 2), the MRP1-mediated efﬂux of rhodamine
which tends to decrease the rhodamine concentration in the
cytosol versus the extracellular one. Under these conditions
it is impossible to determine the gradient of concentration
generated by the pump only. However, experiments per-
formed in the absence of membrane potential, e.g., in K1
buffer, can solve the problem since the gradient of con-
centration through the plasma membrane is then only due to
the pump. The following experiments were therefore per-
formed in such buffer. We have ﬁrst checked that the
MRP1-mediated efﬂux of drug was similar in Na1 and K1
buffers.
Comparison of the MRP1-mediated efﬂux of
daunorubicin (DNR) in the presence and
in the absence of membrane potential
First, we have checked that in K1 buffer plasma and
mitochondrial potentials were dissipated. We have per-
formed a continuous spectroﬂuorometric monitoring of the
ﬂuorescence signal of a cationic rhodamine (TMR 0.2 mM)
during incubation with sensitive cells in a 1-cm quartz
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cuvette containing Na1 buffer on the one hand and K1
buffer on the other hand. In Na1 buffer a strong decrease of
the ﬂuorescence signal was observed due to the accumula-
tion of the lipophilic cation mainly in the mitochondrial
compartments, leading to a quenching of the ﬂuorescence
signal. However, when the same experiments was performed
in K1 buffer, no quenching of the ﬂuorescence was
observed—from which we inferred that there was no
accumulation of TMR inside the cells and therefore that
the potentials were eliminated.
We have measured the accumulation of DNR (cells, 106/
ml, and 1 mM DNR) in GLC4 and GLC4/ADR cells in Na1
and K1 buffers (Dc ¼ 0) respectively, using a method
previously described (Marbeuf-Gueye et al., 1998). We ob-
served that the accumulation of DNR in sensitive cells was
much lower than in sensitive cells and that, in both cases, the
accumulation did not depend on the membrane potentials.
Uptake of rhodamine by GLC4 cells in
the absence of membrane potential
A continuous cytoﬂuorometric monitoring (Facscan) of the
ﬂuorescence signal of sensitive cells incubated in K1 buffer
with various rhodamine concentrations CT (0.02–0.2 mM)
was performed. Fig. 2 shows such a record for Rh6G. Data
points of Fcyto vs. time (or the experimental records) were
ﬁtted to Eq. 13a) and the a- and b-parameters determined
(see Table 1) with b ¼ k/Vcell 3 (1 1 b).
For each concentration the value of Fcyto at steady state
was determined. Fig. 3 shows the plot of Fcyto as a function
of CT ¼ Ce. Actually the accumulation of rhodamine in the
cells being very low, the extracellular concentration was
equal to the total rhodamine concentration added to the cells.
This was veriﬁed as follows: a continuous spectroﬂuoro-
metric monitoring (PerkinElmer LS50B spectroﬂuorometer)
of the ﬂuorescence signal of the rhodamine during in-
cubation with cells in a 1-cm quartz cuvette containing K1
buffer was performed. In a typical experiment, sensitive
cells, 106/ml, were incubated with 0.2 mM rhodamine. No
modiﬁcation of the ﬂuorescence signal was observed versus
time. At steady state, cells were centrifuged and the
ﬂuorescence of the supernatant measured. The intensity of
the signal was very similar to that observed in the presence of
cells. Our conclusion was that it is reasonable, under these
conditions, to consider that Ce is equal to CT.
FIGURE 1 Structure of the rhodamines used.
FIGURE 2 Uptake of Rh 6G by GLC4 cells. Cells, 106/ml, were
incubated with 0.2 mM Rh 6G in K1 buffer. The cytoﬂuorometry signal
(Fcyto) was recorded as a function of time. The data points are from
a representative experiment. They were ﬁtted to Eq. 13a, Fcyto ¼ a 3 [1 3
exp ( b 3 t)], and the coefﬁcients a and b calculated (see Table 1).
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In these experiments, the very important point is that, at
steady state, when Dc ¼ 0, there is a transmembrane
equilibrium—and the free rhodamine activity should be the
same on both sides of the plasma membrane. Here, the
concentrations being low, we have made the reasonable
assumption that concentration could be used in place of
activity, e.g., Ce ¼ Ci, therefore CT ¼ Ci. As can be seen,
there is a linear dependency of Fcyto as a function of CT ¼
Ci:Fcyto ¼ A 3 Ci, where A is a constant which depends on
the nature of the rhodamine. However, the ﬂuorescence
signal recorded from the cells is due not only to the
rhodamine free (Ci) in the cytosol but also to the rhodamine
bound (C) to intracellular sites and the ratio of these two
concentrations is a constant b ¼ C/Ci. As we have shown in
the experimental section, Fcyto¼ F3 (11 b3 r)3 Ci, and
therefore A ¼ F 3 (1 1 b 3 r).
The following experiments were designed to determine b.
In this set of experiments cells were incubated with always
the same rhodamine concentration CT ¼ 0.2 mM but the
number of cells used during the incubation in K1 buffer was
varied from 105 to 53 107 per ml. The ﬂow cytometry signal
was measured at steady state. Fig. 4 shows typical records of
Fcyto as a function of the cells’ number for TMR, Rh 6G, and
RhII. As can be seen, the intensity of the signal decreased
when the number of cells increased. Data points of Fcyto vs.
number of cells were ﬁtted to Eq. 9 and the values of F, r,
and b were estimated. To check if b-values in resistant cells
were similar to those observed in sensitive cells, experiments
were performed with energy-depleted resistant cells. The
values of the three parameters F, r, and b were the same
respectively as those determined for sensitive cells. They are
reported in Table 2. The b-values for RhI and RhII
TABLE 1 Kinetic parameters for rhodamine derivatives and daunorubicin
Rhodamine Ci/Ce a* b 3 103 s1* k 3 1013 L cell1 s1 ka 3 1013 L cell1 s1
Rh I 0.45 6 0.05 91 6 18 12 6 3 1.0 6 0.2 1.2 6 0.2
Rh II 0.35 6 0.04 91 6 18 12 6 2 1.4 6 0.3 2.6 6 0.5
TMR 0.78 6 0.08 278 6 55 6.3 6 1.2 9.3 6 1.6 2.6 6 0.5
Rh 6G 0.55 6 0.05 930 6 180 2.4 6 0.5 1.0 6 0.2 0.8 6 0.2
Daunorubicin 0.30 6 0.04 118 6 24 0.84 6 0.1 3.5 6 0.5 8 6 4
3.1 6 0.5y 13 6 3y
As(OH)3 0.0045 6 0.0010 0.0061 6 0.0015z
GSH 0.0044 6 0.0015§
Calcein 0.006 6 0.002{
Active efﬂux, ka, and passive, k, coefﬁcients. Gradient of concentration Ci/Ce through the plasma membrane generated by MRP1. Data are mean 6 SE of at
least three determinations.
*Eq. 13a was used to ﬁt the data such as those shown in Fig. 2.
yMarbeuf-Gueye et al. (1999).
zSalerno et al. (2002).
§Salerno and Garnier-Suillerot (2001).
{Essodaı¨gui et al. (1998).
FIGURE 3 Intensity of the ﬂow cytometry signal
recorded at steady-state ﬂuorescence from sensitive and
resistant GLC4 cells incubated with Rh6G, Rh I, or RhII.
The intensity of the signal (Fcyto) is plotted as a function of
the extracellular concentration, Ce, of Rhodamine. Cells,
106/ml, were incubated with various concentrations of
rhodamine in K1 buffer. GLC4/ADR cells (); GLC4 cells
(n); and GSH-depleted GLC4/ADR cells (d). The data
points are from a representative experiment.
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rhodamines were comparable; however, the b-value for
TMR was ;15-fold higher. It was then possible to calculate
the k-value (Table 1).
Determination of Ci, the concentration of free
rhodamine in the cytosol of GLC4/ADR
Resistant cells, 106/ml, were incubated in K1 buffer, in the
presence of different concentrations of rhodamine ranging
from 0.02 to 0.2 mM. At steady state, the ﬂow cytometry
signal (Fcyto) was recorded and the plot of Fcyto as a function
of CT is shown in Fig. 3. As can be seen, for a same
extracellular drug concentration, the ﬂuorescence signal is
lower in resistant cells than in sensitive cells. Similar ex-
periments were performed in energy-depleted cells and the
values of Fcyto obtained were similar to that determined for
sensitive cells. This allowed us to say that the A-parameter
value was the same for both sensitive and resistant cells.
Therefore, from the Fcyto value measured in resistant cells we
can easily calculate the Ci value and then the gradient of
concentration Ci/Ce generated by the pump. This calculation
was performed for the various concentrations of rhodamines
used (0.02–0.2 mM), and we did not observe signiﬁcant
variation of the gradient value, indicating that we were
working under conditions where the MRP1 transporter was
far from being saturated. The values of the gradient
generated by the pump are reported in Table 1; they are
within the range of 0.35–0.78.
Determination of the active efﬂux coefﬁcient ka
Once the parameters k, Ce, and Ci were measured, it was easy
to calculate ka according to Eq. 5. The values are reported in
Table 1. For the sake of comparison, the values for DNR are
also shown.
Validation of the method
The method was validated in two different ways.
Using Eq. 13a to ﬁt the data in Fig. 2, we have determined
a and b. On the other hand, using the data of a completely
different set of experiments, and ﬁtting them with Eq. 9, we
have determined F-, b-, and r-values. These values were
then used to recalculate a ¼ (1 1 b 3 r) 3 F 3 Ce. As can
be seen in Tables 1 and 2, the values of a obtained either
from the data Fcyto ¼ f(t) or from the data Fcyto ¼ f(N) (at
steady state) are in good agreement.
We have further validated the method using a totally
different substrate for which the k1/ and ka parameters were
previously determined using a totally different methodology.
FIGURE 4 Intensity of the ﬂow cytometry signal
recorded at steady-state ﬂuorescence from GLC4 cells
incubated with 0.2 mM TMR, Rh 6G, or RhII in K1 buffer.
The intensity of the signal (Fcyto) recorded plotted as
a function of the number of cells per liter. The data points
are from a representative experiment. They were ﬁtted to
Fcyto ¼ F 3 [CT 3 (1 1 b3 r)] / [11 1033 N 3 (1 1
b)], as shown by the solid line, and the values of F, b, and
r were estimated.
TABLE 2
Rhodamine b F 3 106 (1 mM) r a* ¼ (1 1 b 3 r) F 3 Ce
Rh I 7 6 1 380 6 40 0.09 6 0.01 124 6 32
Rh II 11 6 1 450 6 40 0.054 6 0.002 143 6 37
TMR 147 6 15 200 6 20 0.030 6 0.003 216 6 56
Rh 6G 45 6 4 610 6 60 0.10 6 0.1 671 6 175
Parameters characteristic of the interaction of rhodamines with cells; Eq. 9 was used to ﬁt the data, such as shown in Fig. 4. Data are mean 6 SE of three
determinations. b, mean binding constant of rhodamine to cellular components; F, micromolar ﬂuorescence of rhodamine free in the cytosol; and r,
ﬂuorescence quantum yield of rhodamine bound to cellular components.
*The a-parameter from Eq. 13a was calculated using the b-, F-, and r-values.
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For this purpose we have used daunorubicin. We have
recorded Fcyto as a function of time when cells (10
6/mL)
were incubated with 1 mM DNR to avoid accumulation of
the drug (which is a weak base in acidic compartments;
Loetchutinat et al., 2001); the experiments were performed in
the presence of 20 nM concanamycin A. DNR is well-known
to accumulate in the nucleus and therefore the extracellular
concentration cannot be consider as constant. When taken
into account as a function of time, the modiﬁcation of the
extracellular drug concentration is always
Fcyto ¼ að1 exp½b3 tÞ; ð13aÞ
but in the a and b expressions there is a correction factor of
D ¼ 11 ð11bÞ3N3 1093Vcell
and then
a ¼ ð11b3 rÞ3F 3CT=D
and
b ¼ k3D=ð11bÞ3Vcell:
Of course this complete expression can be used for
rhodamines, but in this case, the D-value is close to 1
(because of the relatively low value of b).
The a-, b-, D- and b-values obtained are the following:
a ¼ 118 (ﬂuorescence arbitrary units)
b ¼ 8.4 3 104 s1
D ¼ 1.4
b ¼ 400, which yields k¼ (3.56 0.5)3 1013 L cell–1 s–1.
On the other hand,
Ci/Ce ¼ 0.30 6 0.04, which yields ka ¼ (0.8 6 0.4) 3
1012 L cell–1 s–1.
These values are in good agreement with those previously
obtained with a methodology that we have largely developed
and used for the determination of the rate of uptake and
pump-mediated efﬂux of anthracycline in living cells
(Mankhetkorn et al., 1996; Marbeuf-Gueye et al., 1998).
These values are k ¼ (3.16 0.5)3 1013 L cell–1 s–1 and ka
¼ (1.3 6 0.3) 3 1012 L cell–1 s–1.
Rhodamine uptake in GSH-depleted
GLC4/ADR cells
Cells were incubated in the culture medium for 24 h in the
presence of 25 mM BSO. Under these conditions the con-
centration of GSH remaining inside the cells was\0.2 mM
(Salerno and Garnier-Suillerot, 2001). Cells were then
incubated with 0.2 mM rhodamine. For both cell lines the
uptake was comparable to that observed for sensitive cells.
These results clearly indicate that GSH is involved in the
decrease of rhodamine retention in resistant cells.
Cell-growth inhibition
Cell lines that we used were made resistant by co-culture
with doxorubicin. The IC50 value obtained with RhII for
sensitive and resistant GLC4 cells are 0.09 6 0.02 mM and
0.75 6 0.15 mM, respectively (Fig. 5). These values re-
present means 6 SD of triplicate determinations. The re-
sistance factor was equal to 8. For comparison, the IC50
obtained with doxorubicin under similar experimental con-
ditions were (96 2)3 10 –3 mM and 0. 6706 0.070 mM for
sensitive and resistant cells respectively, with RF ¼ 74.
DISCUSSION
It has long been known that Rh123 is a P-gp substrate. More
recently, the transport of other rhodamines such as TMR, Rh
I, Rh II, and Rh6G by P-gp has been demonstrated (Lu et al.,
2001; Eytan et al., 1997) and the kinetics parameters
characteristic of their transport have been measured (Lu
et al., 2001; Loetchutinat et al., 2003). In the case of MRP1,
these things are far from clear. Zaman et al. (1994) have
demonstrated cross-resistance to Rh123 in MRP1 transfected
SW 1573 cells. Daoud et al. (2000) have shown that the IC50
of HeLa-MRP1 is ;14- and ;ﬁvefold higher than HeLa
cells for VP16 and Rh123 respectively. Minderman et al.
(1996) have demonstrated that in addition to being a substrate
for P-gp, Rh123 is also a substrate for MRP-mediated drug
efﬂux, but that this efﬂux takes place at a slower rate
compared to P-gp. However, the comparison of the uptake of
Rh123 by GLC4/ADR and GLC4 using ﬂow cytometry has
shown that the ﬂuorescence signal recorded from GLC4 was
less than that observed with GLC4/ADR cells (Feller et al.,
1995; Garnier-Suillerot, unpublished data). More recently,
Daoud et al. (2000) have reported on the characterization of
FIGURE 5 Effects of RhII on the growth of GLC4 and GLC4/ADR cells.
Cells were seeded at 105 cells/ml and grown in the absence and the presence
of increasing concentrations of RhII (0–10 mM). Cell numbers were
determined 72 h later. Cell growth is expressed as % of control in the
absence of drug. GLC4 cells (d); and GLC4/ADR cells (). The data points
are from a representative experiment.
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MRP1 interactions with Rh123 using the photoactive analog
iodoaryl azido Rh123, and shown that it interacts directly
and speciﬁcally with MRP1.
To our knowledge, up to now the MRP1-mediated efﬂux
of one rhodamine only, Rh123, has been explored and no
study was designed to determine the kinetics parameters of
this transport.
Measurement of the kinetic characteristics of substrate
transport is a powerful approach to enhancing our under-
standing of their function and mechanism. In this article, we
present data that characterized the transport of several
rhodamine analogs which are positively charged. We took
advantage of the intrinsic ﬂuorescence of rhodamines, and
performed a ﬂow-cytometric analysis of dye accumulation in
the wild-type, drug-sensitive GLC4 cells that do not express
MRP1. For its MDR subline, which displays high level of
MRP1, the resistance factor for daunorubicin was equal to 23
(Marbeuf-Gueye et al., 1999). The measurements were made
in real-time using intact GLC4/ADR and GLC4 cells. We
clearly show that GLC4/ADR cells are cross-resistant to
rhodamines, that there is an energy-dependent efﬂux of
rhodamines in GLC4/ADR cells, and that this efﬂux is GSH-
dependent inasmuch as no efﬂux was observed after GSH
depletion with BSO. Rh123 is widely used as a structural
marker for mitochondria as an indicator of mitochondrial
activity and, therefore, the relative accumulation of posi-
tively charged rhodamine in parental and resistant cells is
likely to be inﬂuenced by any differences in mitochondrial
number or membrane potential between the cell types in
addition to effects of active transporters. For this reason we
have studied the MRP1-mediated efﬂux of rhodamine in the
absence of membrane potential after having checked that the
MRP1-mediated efﬂux of drug (in this case, daunorubicin)
was not potential-dependent.
To characterize the MRP1-mediated efﬂux of rhodamines,
the parameter ka was calculated. As shown (Materials and
Methods, this article; and Marbeuf-Gueye et al., 1998,
1999), ka is proportional to the ratio VM/Km and is very
convenient to evaluate the efﬁciency of a transporter for any
substrate. The determination of ka requires the measurement
of the gradient of concentration, i.e., Ce vs. Ci, which is
generated by the presence of the pump. Thanks to the use of
two independent ﬂuorometric techniques, macroﬂuorescence
and ﬂow-cytometry, it is possible to directly determine the
free rhodamine concentration in the cytosol and in the
extracellular medium. Actually, our data clearly show that
the cytoﬂuorometric signal, in cells without membrane
potential, is proportional to the amount of rhodamine free in
the cytosol. This observation allows the further determina-
tion of the concentration of drug free in the cytosol of
resistant cells. The determination of ka also requires the
measurement of the rate of passive diffusion of the dye
through the plasma membrane. For this reason, we have
determined the ratio of the drug bound to the drug free in the
cytosol, which subsequently allows the determination of the
real number of molecules that penetrate per second into one
cell and therefore the true rate of passive diffusion of the dye.
As can be seen in Table 1, the ka values determined for the
four molecules are of the same order of magnitude, ranging
from 0.8 to 2.63 1013 L cell1 s1. One of our aims was to
compare the MRP1-mediated efﬂux of these rhodamine
analogs to that of other substrates obtained previously us-
ing the same cell line. To help this comparison, the values of
Ci/Ce, k, and ka for daunorubicin are reported in Table 1,
together with the ka value for GSH, calcein, and As(OH)3.
Compared to previously published data, the efﬁciency of the
MRP1-mediated rhodamine pumping is ;10-fold less than
for anthracycline (Marbeuf-Gueye et al., 1999) but ;100-
fold more than for GSH (Salerno and Garnier-Suillerot,
2001), calcein (Essodaı¨gui et al., 1998), and As(OH)3
(Salerno et al., 2002). In addition, the present study shows
that the efﬁciency of the MRP1-mediated rhodamine
pumping is ;10-fold less than the efﬁciency of the P-gp-
mediated rhodamine pumping, whereas the efﬁciency of the
anthracycline pumping was very similar for both trans-
porters.
The ﬁndings presented here are the ﬁrst to show
quantitative information about the kinetics parameters for
MRP1-mediated efﬂux of rhodamine analogs in intact cells.
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